en English
af Afrikaanssq Albanianam Amharicar Arabichy Armenianaz Azerbaijanieu Basquebe Belarusianbn Bengalibs Bosnianbg Bulgarianca Catalanceb Cebuanony Chichewazh-CN Chinese (Simplified)zh-TW Chinese (Traditional)co Corsicanhr Croatiancs Czechda Danishnl Dutchen Englisheo Esperantoet Estoniantl Filipinofi Finnishfr Frenchfy Frisiangl Galicianka Georgiande Germanel Greekgu Gujaratiht Haitian Creoleha Hausahaw Hawaiianiw Hebrewhi Hindihmn Hmonghu Hungarianis Icelandicig Igboid Indonesianga Irishit Italianja Japanesejw Javanesekn Kannadakk Kazakhkm Khmerko Koreanku Kurdish (Kurmanji)ky Kyrgyzlo Laola Latinlv Latvianlt Lithuanianlb Luxembourgishmk Macedonianmg Malagasyms Malayml Malayalammt Maltesemi Maorimr Marathimn Mongolianmy Myanmar (Burmese)ne Nepalino Norwegianps Pashtofa Persianpl Polishpt Portuguesepa Punjabiro Romanianru Russiansm Samoangd Scottish Gaelicsr Serbianst Sesothosn Shonasd Sindhisi Sinhalask Slovaksl Slovenianso Somalies Spanishsu Sudanesesw Swahilisv Swedishtg Tajikta Tamilte Teluguth Thaitr Turkishuk Ukrainianur Urduuz Uzbekvi Vietnamesecy Welshxh Xhosayi Yiddishyo Yorubazu Zulu

Advocate’s Blog

Alterity reports additional support for ATH 434

Alterity reports additional support for ATH 434

ALTERITY PRESS RELEASE: MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 4 November 2021: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative...

MODAG Collaboration Update – MSA Drug

MODAG Collaboration Update – MSA Drug

Congratulations to MODAG! On behalf of MSA/AMS patients around the world, we are thankful for your efforts! 💜. https://www.tevapharm.com/news-and-media/latest-news/teva-and-modag-announce-licensing-collaboration-for-neurodegenerative-disease-drug-candidate/

MSA BLOGS 

Caregiver’s Blog

Lundbeck Launches Phase 2 Study for MSA

Lundbeck Launches Phase 2 Study for MSA

Good news from Lundbeck!  The company plans to initiate Phase 2 Study for Potential Treatment for Multiple System Atrophy! --- Press Release (Mon, Nov 08, 2021 09:00 CET) H. Lundbeck A/S (Lundbeck), announces that it has expanded its clinical-stage pipeline and is...

Alterity reports additional support for ATH 434

Alterity reports additional support for ATH 434

ALTERITY PRESS RELEASE: MELBOURNE, AUSTRALIA AND SAN FRANCISCO, USA – 4 November 2021: Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative...

Researcher’s Blog

MODAG Collaboration Update – MSA Drug

MODAG Collaboration Update – MSA Drug

Congratulations to MODAG! On behalf of MSA/AMS patients around the world, we are thankful for your efforts! 💜. https://www.tevapharm.com/news-and-media/latest-news/teva-and-modag-announce-licensing-collaboration-for-neurodegenerative-disease-drug-candidate/

*NEW * RESEARCH UPDATE FROM BIOHAVEN RE: VERDIPERSTAT (BHV-3241)

*NEW * RESEARCH UPDATE FROM BIOHAVEN RE: VERDIPERSTAT (BHV-3241)

Timeline: International Phase 3 Clinical Trial of Verdiperstat in Multiple System Atrophy "Top line results from the study are expected to be available in 3Q2021 and will help to characterize the potential benefits and risks of Verdiperstat in MSA. After the study...

POSSIBLE NEW DRUG

POSSIBLE NEW DRUG

Curious about the possible new drug being studied that might slow MSA? See this graphic for information about the mechanism of action (MOA). For Research Updates & More, Register on the Hub: https://defeatmsa.org/research-registry/ #defeatmsa #kickmsa...

Patient’s Blog

No Results Found

The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.

You May Also Like…

English